Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAENNEC in Shoulder Impingement Syndrome
NCT05528705Completed
- Sponsor
- GC Wellbeing
- Start
- Sep 2022
- Primary completion
- Oct 2023
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Randomised, single-blind trial of LAENNEC in shoulder impingement syndrome (SIS) (2 arms), sponsored by GC Wellbeing. Primary endpoint: Visual Analogue Scale at 12 weeks. Started Sep 2022; status: completed.
02
Drugs
LAENNEC
03
Conditions
shoulder impingement syndrome (SIS)
Beyond the preview
Go deeper on NCT05528705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05528705.